B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Mayo Clinic
Baylor College of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Baylor College of Medicine
University of California, San Francisco
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
Baylor College of Medicine
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
University of California, San Diego
City of Hope Medical Center
Case Comprehensive Cancer Center
University of Pennsylvania
OHSU Knight Cancer Institute
Case Comprehensive Cancer Center
University of California, San Diego
Mayo Clinic
City of Hope Medical Center
Dana-Farber Cancer Institute
University of Maryland, Baltimore
Jonsson Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Roswell Park Cancer Institute
Case Comprehensive Cancer Center
University Health Network, Toronto
Mayo Clinic
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
University of California, Davis
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Calibr, a division of Scripps Research
Stanford University
University Hospital Tuebingen
Dana-Farber Cancer Institute
Cedars-Sinai Medical Center
Medical College of Wisconsin
Calibr, a division of Scripps Research
Institute of Hematology & Blood Diseases Hospital, China
University of California, San Diego
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
OHSU Knight Cancer Institute
Stanford University
M.D. Anderson Cancer Center